Aptevo Therapeutics Inc. secures a $60 million equity line of credit to support the advancement of its multispecific portfolio.
The facility is expected to extend Aptevo's funding runway into 2029, enabling the achievement of key clinical and preclinical milestones.
The equity line of credit offers added financial flexibility without requiring the Company to draw on the facility immediately.
Financial Flexibility and Strategic Optionality
The equity line of credit provides Aptevo with access to capital at its discretion, allowing incremental fund raising under market-based conditions.
Extended Funding Runway
The fully leveraged facility, along with existing cash reserves, is projected to fund Aptevo until 2029, supporting continued clinical data generation and asset advancement.
Portfolio Advancement
The funds will be used to support ongoing clinical developments, preclinical programs, and general corporate purposes.
- The equity line of credit strengthens Aptevo's financial position, offering control over capital access and affordable financing options.
- With this funding, Aptevo can focus on executing its clinical data generation plan and advancing its differentiated assets across the portfolio.
Aptevo Therapeutics' strategic move to secure the equity line of credit enhances its financial flexibility and supports the ongoing development of its innovative immune-oncology therapeutics. The extended funding runway underscores the Company's commitment to value creation and clinical advancement.